Table 1.

Patient characteristics

No.Median (range)
Age (y)54 (39-78)
Sex: male/female15/8
Race: Caucasian/Blacks18/5
Isotype: Ig G/A/LC11/4/8
No. of prior regimens7 (3-13)
SCT-Autologous/tandem/allo20/6/1
Prior thalidomide/lenalidomide23/17
Bortezomib19
    Duration (mo)6 (2-40)
    No. of regimens 1/2/38/5/6
    Primary refractory9
    Responsive then progressive10
ECOG1 (0-2)
Time from diagnosis to study (y)5.7 (1.8-9)
Time from last therapy (d)20 (15-39)
Creatinine (mg/dl)1.3 (0.7-2.1)
Hgb (g/dl)11 (8.5-14)
Platelets (x103/μL)148 (62-253)
Albumin (g/dl)3.8 (2.5-4.7)
LDH (Units/L)209 (104-619)
β-2-Microglobulin (mg/L)3 (1.3-6)
Baseline peripheral neuropathy13
Grade 1/211/2
Abnormal karyotype14
11;146
Hypodeploidy: del(13), del(17)7/3
Dup, der, del(1)9